Mesothelioma Therapy Immunotherapy and Targeted Therapy 3

Question 1

Which immune checkpoint combination showed a statistically significant overall survival benefit in CheckMate 743 for mesothelioma?

Accepted Answer

Nivolumab + ipilimumab vs. chemotherapy

Answer

CheckMate 743 demonstrated a statistically significant overall survival benefit for nivolumab + ipilimumab versus standard chemotherapy in unresectable pleural mesothelioma.

Question 2

Tumor Treating Fields (TTFields) therapy is approved in the US for mesothelioma in combination with which treatment?

Accepted Answer

Pemetrexed + platinum chemotherapy

Answer

TTFields (NovoTTF-100L) received FDA approval in combination with pemetrexed + platinum chemotherapy for unresectable pleural mesothelioma.

Question 3

What is the mechanism of Tumor Treating Fields (TTFields) therapy?

Accepted Answer

Creating alternating electric fields that disrupt cancer cell division

Answer

TTFields uses low-intensity, alternating electric fields to disrupt microtubule formation during cell division, selectively killing rapidly dividing cancer cells.

Question 4

Which serum biomarker may be used to monitor response to immunotherapy in mesothelioma?

Accepted Answer

Soluble mesothelin-related peptides (SMRP)

Answer

Soluble mesothelin-related peptides (SMRP) is a serum biomarker that may be useful in monitoring treatment response in mesothelioma patients.

Question 5

Which genetic pathway alteration is under investigation as a target in sarcomatoid mesothelioma?

Accepted Answer

SWI/SNF chromatin remodeling complex (SMARCA4/ARID1A)

Answer

Mutations in the SWI/SNF chromatin remodeling complex, including SMARCA4 and ARID1A, are being investigated as therapeutic targets in sarcomatoid mesothelioma.

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Practice Test

Mesothelioma Therapy Immunotherapy and Targeted Therapy 3